Identification of progression markers in B-CLL by gene expression profiling

Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial

“…Paradoxically, expression of PPP2R5C has been reported to be down-regulated in progressive CLL. 20 Five correlated SNP mapping to 4p16.1 showed an association with progression-free survival (rs747580, rs2631731, rs940136, rs2631753, rs1949733), the strongest association being shown for rs1949733 (P=8.22¥10 -7 ). Hazard ratios for heterozygosity and AA homozygosity were 1.54 (95% CI: 1.21-1.97), and 2.36 (95% CI: 1.60-3.47), respectively; corresponding 5-year progression-free survival rates were 24.4% (95% CI: 18.9-31.5%), 11.9% (95% CI: 7.5-18.8%) and 3.1% (95% CI: 0.5-21.5%), respectively ( Figure 2E).…”

Ser/Thr Phosphatases: The New Frontier for Myeloid Leukemia Therapy?

“…Decreased expression was identified in primary human melanoma samples compared to melanocytic nevi (Deichmann et al 2001), and in human lung cancer cell lines where subsequent overexpression of B56 reversed the tumorigenic phenotype (Chen et al 2004). Reduced transcript levels of B56 have also been documented in patients with aggressive B-CLL compared to those with stable disease (Falt et al 2005). A mutation in B56 has also been observed in lung cancer, and this was shown to disrupt the interaction of B56 with p53 (Shouse et al 2010).…”

Current Knowledge of Microarray Analysis for Gene Expression Profiling in Chronic Lymphocytic Leukemia

“…GEP in CLL, which may predict a good prognosis. (Edelmann et al, 2008;Fält et al, 2005;Fernandez et al, 2008;Ferrer et al, 2004;Stratowa et al, 2001) www.intechopen.com…”

“…With the aim of identifying genes potentially related to disease progression, Fält et al, (2005) performed gene expression profiling on CLL patients with non-aggressive disease or with progressive disease requiring therapy. The Affymetrix GeneChip U95Av2 technique was used in 11 samples obtained from CLL patients with stable and 10 patients with clinically progressive disease.…”